Recursion Reports Phase 2 REC-4881 Polyp Reductions
New analyses from the ongoing Phase 2 TUPELO trial showed polyp burden reductions across the GI tract, including larger, higher-risk polyps. Recursion anticipates starting a registrational trial in the second half of 2027, pending ongoing FDA discussions.
Story updates
09:30:22 PM UTC
SquawkNews
RECURSION PHARMACEUTICALS - NEARLY 50% UPPER GI &33% LOWER GI PATIENTS ACHIEVE ≥65% POLYP BURDEN RED
09:30:29 PM UTC
SquawkNews
RECURSION PHARMACEUTICALS - TO INITIATE REGISTRATIONAL TRIAL FOR REC-4881 IN SECOND HALF OF 2027
09:41:52 PM UTC
SquawkNews
REC-4881 de Recursion reduce un 47% la mediana de carga de pólipos en ensayo de fase 2 Recursion
09:41:57 PM UTC
SquawkNews
Recursion's REC-4881 shows 47% median reduction in polyp burden in Phase 2 FAP trial Recursion r
Recursion reported new analyses from its ongoing Phase 2 TUPELO trial showing polyp burden reductions across the GI tract, including larger, higher-risk polyps. The company anticipates starting a registrational trial in the second half of 2027, pending ongoing FDA discussions.Material DetailsContex…